ACCC COVID-19 Resource Center & Discussion Group
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for the MULTIDISCIPLINARY CANCER CARE TEAM and the PATIENTS THEY SERVE since 1993
Meetings & Education
State Society Education Series
NCOA Advocacy Support
Patient Advocacy Organizations
State & Federal Resources
Off-Label Use Literature
Find A Clinical Trial
National Professional Organizations
Financial Advocacy & Patient Assistance
NCOA Corporate Members
Become a Corporate Member
Industry News Archive
COVID-19 Featured Resources
FDA Restricts Use of Keytruda and Tecentriq for Urothelial Cancer
On June 20, 2018, the FDA announced that it was restricting the use of Keytruda (pembrolizumab) and Tecentriq (atezolizumab) for patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing therapy.
This restriction results from decreased survival associated with the use of Keytruda or Tecentriq as monotherapy compared to platinum-based chemotherapy in clinical trials to treat patients with metastatic urothelial cancer who have not received prior therapy and who have low expression of the protein programmed death ligand 1 (PD-L1).
Read the full FDA announcement here.